Clinical Data Revolution rockets on strong pancreatic cancer data PharmaphorumRevolution Medicines thinks it could transform the treatment of pancreatic cancer based on phase 3 data with its pan-RAS(on) inhibitor daraxonrasib.Clinical DataOncologyRead full story pharminent April 14, 2026 (Last updated: April 14, 2026) Pharmaphorum Revolution Medicines thinks it could transform the treatment of pancreatic cancer based on phase 3 data with its pan-RAS(on) inhibitor daraxonrasib. Clinical DataOncologyRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: MSD, Daiichi Sankyo’s ifinatamab deruxtecan receives FDA priorityNext: Novo Nordisk and OpenAI forge alliance to drive speedy drug development Related Stories Clinical Data AstraZeneca, Ionis drug fails big heart disease study in major setback pharminent July 9, 2026 Clinical Data Roche’s KRAS drug tops its rivals in lung cancer trial pharminent July 2, 2026 Clinical Data EAN 2026: Real-world data supports safety and efficacy of AbbVie’s Vyalev in Parkinson’s pharminent July 1, 2026
